Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells

por Agarwal, S, Zerillo, C, Kolmakova, J, Christensen, J G, Harris, L N, Rimm, D L, DiGiovanna, M P, Stern, D F
Publicado 2009

Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification

por Betof, A S, Rabbani, Z N, Hardee, M E, Kim, S J, Broadwater, G, Bentley, R C, Snyder, S A, Vujaskovic, Z, Oosterwijk, E, Harris, L N, Horton, J K, Dewhirst, M W, Blackwell, K L
Publicado 2012

Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from...

por Jhaveri, K.L., Wang, X.V., Makker, V., Luoh, S.-W., Mitchell, E.P., Zwiebel, J.A., Sharon, E., Gray, R.J., Li, S., McShane, L.M., Rubinstein, L.V., Patton, D., Williams, P.M., Hamilton, S.R., Conley, B.A., Arteaga, C.L., Harris, L.N., O’Dwyer, P.J., Chen, A.P., Flaherty, K.T.
Publicado 2021

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial

por Mansfield, A. S., Wei, Z., Mehra, R., Shaw, A. T., Lieu, C. H., Forde, P. M., Drilon, A. E., Mitchell, E. P., Wright, J. J., Takebe, N., Sharon, E., Hovelson, D., Tomlins, S., Zeng, J., Poorman, K., Malik, N., Gray, R. J., Li, S., McShane, L. M., Rubinstein, L. V., Patton, D., Williams, P. M., Hamilton, S. R., Conley, B. A., Arteaga, C. L., Harris, L. N., O’Dwyer, P. J., Chen, A. P., Flaherty, K. T.
Publicado 2022